https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/ 2024-02-09T16:33:45+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/towards-more-diversity-in-neuro-oncology-leadership-the-divine-initiative/ 2024-02-09T16:33:45+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/gender-disparity-regarding-work-life-balance-satisfaction-among-german-neuro-oncologists-a-youngnoa-survey/ 2023-01-29T20:17:55+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/focal-cavity-radiotherapy-after-neurosurgical-resection-of-brain-metastases-sparing-neurotoxicity-without-compromising-locoregional-control/ 2022-11-23T14:00:52+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/focal-cavity-radiotherapy-after-neurosurgical-resection-of-brain-metastases-sparing-neurotoxicity-without-compromising-locoregional-control-2/ 2022-11-23T13:55:47+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/multicenter-pilot-study-of-radio-chemotherapy-as-first-line-treatment-for-adults-with-medulloblastoma-noa-07-2/ 2022-11-09T15:22:51+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/quality-of-life-in-the-glarius-trial-randomizing-bevacizumab-irinotecan-versus-temozolomide-in-newly-diagnoses-mgmt-nonmethylated-glioblastoma-2/ 2022-11-09T15:22:48+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/feasibility-of-real-time-molecular-profiling-for-patients-with-newly-diagnosed-glioblastoma-without-mgmt-promotor-hypermethylation-the-nct-neuro-master-match-n%c2%b2m%c2%b2-pilot-study-2/ 2022-11-09T15:22:45+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/superiority-of-temozolomide-over-radiotherapy-for-elderly-patients-with-rtk-ii-methylation-class-mgmt-promotor-methylated-malignant-astrocytoma-3/ 2022-11-09T15:21:23+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/baseline-t1-hyperintense-and-diffusion-restricted-lesions-are-not-linked-to-prolonged-survival-in-bevacizumab-treated-glioblastoma-patients-of-the-glarius-trail-2/ 2022-11-09T15:21:19+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/intraoperative-radiotherapy-with-low-energy-x-rays-after-neurosurgical-resection-of-brain-metastases-2/ 2022-11-09T15:20:56+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/multicenter-pilot-study-of-radio-chemotherapy-as-first-line-treatment-for-adults-with-medulloblastoma-noa-07/ 2022-11-09T15:17:37+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/quality-of-life-in-the-glarius-trial-randomizing-bevacizumab-irinotecan-versus-temozolomide-in-newly-diagnoses-mgmt-nonmethylated-glioblastoma/ 2022-11-09T15:17:33+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/feasibility-of-real-time-molecular-profiling-for-patients-with-newly-diagnosed-glioblastoma-without-mgmt-promotor-hypermethylation-the-nct-neuro-master-match-n%c2%b2m%c2%b2-pilot-study/ 2022-11-09T15:17:32+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/superiority-of-temozolomide-over-radiotherapy-for-elderly-patients-with-rtk-ii-methylation-class-mgmt-promotor-methylated-malignant-astrocytoma/ 2022-11-09T15:16:47+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/intraoperative-radiotherapy-with-low-energy-x-rays-after-neurosurgical-resection-of-brain-metastases/ 2022-11-09T15:16:43+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/a-vaccine-targeting-mutant-idh1-in-newly-diagnosed-glioma-2/ 2022-11-07T13:35:21+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/a-vaccine-targeting-mutant-idh1-in-newly-diagnosed-glioma/ 2022-11-07T04:48:56+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/german-cancer-society-neuro-oncology-working-group-noa-03-multicenter-trial-of-single-agent-high-dose-methotrexate-for-primary-central-nervous-system-lymphoma/ 2022-11-04T14:14:19+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/german-cancer-society-neuro-oncology-working-group-noa-03-multicenter-trial-of-single-agent-high-dose-methotrexate-for-primary-central-nervous-system-lymphoma-2/ 2022-11-04T14:14:05+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/neuro-oncology-working-group-01-trial-of-nimustine-plus-teniposide-versus-nimustine-plus-cytarabine-chemotherapy-in-addition-to-involved-field-radiotherapy-in-the-first-line-treatment-of-malignant-g-2/ 2022-11-04T14:13:27+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/neuro-oncology-working-group-01-trial-of-nimustine-plus-teniposide-versus-nimustine-plus-cytarabine-chemotherapy-in-addition-to-involved-field-radiotherapy-in-the-first-line-treatment-of-malignant-gli/ 2022-11-04T14:13:21+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/noa-03-trial-of-high-dose-methotrexate-in-primary-central-nervous-system-lymphoma-final-report-2/ 2022-11-04T14:12:36+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/noa-03-trial-of-high-dose-methotrexate-in-primary-central-nervous-system-lymphoma-final-report/ 2022-11-04T14:12:29+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/noa-04-randomized-phase-iii-trial-of-sequential-radiochemotherapy-of-anaplastic-glioma-with-procarbazine-lomustine-and-vincristine-or-temozolomide-2/ 2022-11-04T14:12:23+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/noa-04-randomized-phase-iii-trial-of-sequential-radiochemotherapy-of-anaplastic-glioma-with-procarbazine-lomustine-and-vincristine-or-temozolomide/ 2022-11-04T14:12:15+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/pet-for-radiation-treatment-planning-of-brain-tumors-2/ 2022-11-04T14:12:08+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/pet-for-radiation-treatment-planning-of-brain-tumors/ 2022-11-04T14:12:03+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/high-dose-methotrexate-with-or-without-whole-brain-radiotherapy-for-primary-cns-lymphoma-g-pcnsl-sg-1-a-phase-3-randomised-non-inferiority-trail-2/ 2022-11-04T14:12:00+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/high-dose-methotrexate-with-or-without-whole-brain-radiotherapy-for-primary-cns-lymphoma-g-pcnsl-sg-1-a-phase-3-randomised-non-inferiority-trail/ 2022-11-04T14:11:55+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/patients-with-idh1-wild-type-anaplastic-astrocytoms-exhibit-worse-prognosis-than-idh1-mutated-glioblastomas-and-idh1-mutation-status-accounts-for-the-unfavorable-prognostic-effect-of-higher-age-impl-2/ 2022-11-04T14:10:46+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/patients-with-idh1-wild-type-anaplastic-astrocytoms-exhibit-worse-prognosis-than-idh1-mutated-glioblastomas-and-idh1-mutation-status-accounts-for-the-unfavorable-prognostic-effect-of-higher-age-impl/ 2022-11-04T14:10:35+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/an-interindividual-comparison-of-o-2-18ffluorethyl-l-tyrosine-fet-and-l-methyl-11cmethionine-met-pet-in-patients-with-brain-gliomas-and-metastases-3/ 2022-11-04T14:10:29+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/an-interindividual-comparison-of-o-2-18ffluorethyl-l-tyrosine-fet-and-l-methyl-11cmethionine-met-pet-in-patients-with-brain-gliomas-and-metastases-2/ 2022-11-04T14:10:20+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/temozolomide-and-13-cis-retinoic-acid-in-patients-with-anaplastic-gliomas-a-prospective-single-arm-monocentric-phase-ii-study-rnop-05-2/ 2022-11-04T14:10:17+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/temozolomide-and-13-cis-retinoic-acid-in-patients-with-anaplastic-gliomas-a-prospective-single-arm-monocentric-phase-ii-study-rnop-05/ 2022-11-04T14:10:15+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/noa-05-phase-2-trial-of-procarbazine-and-lomustine-therapy-in-gliomatosis-cerebri-2/ 2022-11-04T14:10:12+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/noa-05-phase-2-trial-of-procarbazine-and-lomustine-therapy-in-gliomatosis-cerebri/ 2022-11-04T14:10:04+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/outcome-of-elderly-patients-with-primary-cns-lymphoma-in-the-g-pcnsl-sg-1/ 2022-11-04T14:09:50+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/outcome-of-elderly-patients-with-primary-cns-lymphoma-in-the-g-pcnsl-sg-1-2/ 2022-11-04T14:08:36+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/surgery-of-primary-cns-lymphoma-challenging-a-paradigm-2/ 2022-11-04T14:08:34+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/surgery-of-primary-cns-lymphoma-challenging-a-paradigm/ 2022-11-04T14:08:26+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/temozolomide-chemotherapy-alone-versus-radiotherapy-alone-for-malignant-astrocytoma-in-the-elderly-the-noa-08-randomised-phase-3-trial-2/ 2022-11-04T14:08:23+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/temozolomide-chemotherapy-alone-versus-radiotherapy-alone-for-malignant-astrocytoma-in-the-elderly-the-noa-08-randomised-phase-3-trial/ 2022-11-04T14:08:20+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/prognostic-impact-of-meningeal-dissemination-in-primary-cns-lymphoma-pcnsl-experience-from-the-g-pcnsl-sg1-trial/ 2022-11-04T14:08:19+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/prognostic-impact-of-meningeal-dissemination-in-primary-cns-lymphoma-pcnsl-experience-from-the-g-pcnsl-sg1-trial-2/ 2022-11-04T14:08:16+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/pathogenesis-and-management-of-primary-cns-lymphoma/ 2022-11-04T14:08:14+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/pathogenesis-and-management-of-primary-cns-lymphoma-2/ 2022-11-04T14:08:13+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/malignant-astrocytoms-of-elderly-patients-lack-favorable-molecular-markers-an-analysis-of-the-noa-08-study-collective-2/ 2022-11-04T14:08:09+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/malignant-astrocytoms-of-elderly-patients-lack-favorable-molecular-markers-an-analysis-of-the-noa-08-study-collective/ 2022-11-04T14:08:09+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/atrx-loss-refines-the-classification-of-anaplastic-gliomas-and-identifies-a-subgroup-of-idh-mutant-astrocytic-tumors-wit-better-prognosis-3/ 2022-11-04T14:07:52+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/atrx-loss-refines-the-classification-of-anaplastic-gliomas-and-identifies-a-subgroup-of-idh-mutant-astrocytic-tumors-wit-better-prognosis-2/ 2022-11-04T14:07:43+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/18-ffet-pet-imaging-for-treatment-and-response-monitoring-of-radiation-therapy-in-malignant-glioma-patients-a-review-3/ 2022-11-04T14:06:24+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/18-ffet-pet-imaging-for-treatment-and-response-monitoring-of-radiation-therapy-in-malignant-glioma-patients-a-review-2/ 2022-11-04T14:06:15+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/prognostic-or-predictive-value-of-mgmt-promotor-methylation-in-gliomas-depends-on-idh1-mutation/ 2022-11-04T14:06:08+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/prognostic-or-predictive-value-of-mgmt-promotor-methylation-in-gliomas-depends-on-idh1-mutation-2/ 2022-11-04T14:06:05+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/distribution-of-tert-promotor-mutations-in-pediatric-and-adult-tumors-of-the-nervous-system/ 2022-11-04T14:06:04+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/distribution-of-tert-promotor-mutations-in-pediatric-and-adult-tumors-of-the-nervous-system-2/ 2022-11-04T14:06:03+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/integrated-dna-methylation-and-copy-number-profiling-identifies-three-clinically-and-biologically-relevant-groups-of-anaplastic-glioma/ 2022-11-04T14:06:01+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/integrated-dna-methylation-and-copy-number-profiling-identifies-three-clinically-and-biologically-relevant-groups-of-anaplastic-glioma-2/ 2022-11-04T14:05:52+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/mgmt-testing-the-challenges-for-biomarker-based-glioma-treatment/ 2022-11-04T14:04:24+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/mgmt-testing-the-challenges-for-biomarker-based-glioma-treatment-2/ 2022-11-04T14:04:21+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/assessing-cpg-island-methylator-phenotype-1p-19q-codeletion-and-mgmt-promotor-methylation-from-epigenome-wide-data-in-the-biomarker-cohort-of-the-noa-04-trial/ 2022-11-04T14:04:15+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/assessing-cpg-island-methylator-phenotype-1p-19q-codeletion-and-mgmt-promotor-methylation-from-epigenome-wide-data-in-the-biomarker-cohort-of-the-noa-04-trial-4/ 2022-11-04T14:04:14+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/differently-regulated-mirnas-as-prognostic-biomarkers-in-the-blood-of-primary-cns-lymphoma-patients/ 2022-11-04T14:04:13+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/whole-brain-irradiation-with-hippocampal-sparing-and-dose-escalation-on-multiple-brain-metastases-local-tumour-control-and-survival/ 2022-11-04T14:04:10+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/differently-regulated-mirnas-as-prognostic-biomarkers-in-the-blood-of-primary-cns-lymphoma-patients-2/ 2022-11-04T14:04:10+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/prognostic-impact-of-intraocular-involvement-in-primary-cns-lymphoma-experience-from-the-g-pcnsl-sg1-trial/ 2022-11-04T14:03:51+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/whole-brain-irradiation-with-hippocampal-sparing-and-dose-escalation-on-multiple-brain-metastases-local-tumour-control-and-survival-2/ 2022-11-04T14:03:34+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/molecullar-classification-of-diffuse-cerebral-who-grade-ii-iii-gliomas-using-genome-and-transcriptome-wide-profiling-improves-stratification-of-prognostically-distinct-patient-groups/ 2022-11-04T14:02:37+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/prognostic-impact-of-intraocular-involvement-in-primary-cns-lymphoma-experience-from-the-g-pcnsl-sg1-trial-2/ 2022-11-04T14:02:37+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/molecullar-classification-of-diffuse-cerebral-who-grade-ii-iii-gliomas-using-genome-and-transcriptome-wide-profiling-improves-stratification-of-prognostically-distinct-patient-groups-2/ 2022-11-04T14:02:35+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/mgmt-promotor-methylation-is-a-strong-prognostic-biomarker-for-benefit-from-dose-intensified-temozolomide-rechallenge-in-progressive-glioblastoma-the-director-trail/ 2022-11-04T14:02:35+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/mgmt-promotor-methylation-is-a-strong-prognostic-biomarker-for-benefit-from-dose-intensified-temozolomide-rechallenge-in-progressive-glioblastoma-the-director-trail-2/ 2022-11-04T14:02:33+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/complete-resection-of-contrast-enhancing-tumor-volume-is-associated-with-improved-survival-in-recurrent-glioblastoma-results-from-the-director-trial/ 2022-11-04T14:02:24+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/complete-resection-of-contrast-enhancing-tumor-volume-is-associated-with-improved-survival-in-recurrent-glioblastoma-results-from-the-director-trial-2/ 2022-11-04T14:02:24+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/long-term-analysis-of-the-noa-04-randomized-phase-iii-trial-of-sequential-radiochemotherapy-of-anaplastic-glioma-with-pcv-or-temozolomide/ 2022-11-04T14:02:13+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/long-term-analysis-of-the-noa-04-randomized-phase-iii-trial-of-sequential-radiochemotherapy-of-anaplastic-glioma-with-pcv-or-temozolomide-2/ 2022-11-04T14:01:58+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/bevacizumab-plus-irinotecan-versus-temozolomide-in-newly-diagnosed-06-methylguanine-dna-methyltransferase-nonmethylated-glioblastoma-the-randomized-glarius-trial/ 2022-11-04T14:01:27+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/phase-iii-trial-of-ccnu-temozolomide-tmz-combination-therapy-vs-standard-tmz-therapy-for-newly-diagnosed-mgmt-methylated-glioblastoma-patients-the-ceteg-noa-09-trial/ 2022-11-04T14:00:50+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/adjuvant-stereotactic-fractionated-radiotherapy-to-the-resection-cavity-in-recurrent-glioblastoma-the-gliocave-study-noa-17-aro-2016-3-dktk-rog-trial-2/ 2022-11-04T14:00:25+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/phase-iii-trial-of-ccnu-temozolomide-tmz-combination-therapy-vs-standard-tmz-therapy-for-newly-diagnosed-mgmt-methylated-glioblastoma-patients-the-ceteg-noa-09-trial-2/ 2022-11-04T14:00:15+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/adjuvant-stereotactic-fractionated-radiotherapy-to-the-resection-cavity-in-recurrent-glioblastoma-the-gliocave-study-noa-17-aro-2016-3-dktk-rog-trial-3/ 2022-11-04T13:59:36+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/tumor-growth-patterns-of-mgmt-non-methylated-glioblastoma-in-the-randomized-glarius-trail/ 2022-11-04T13:59:10+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/tumor-growth-patterns-of-mgmt-non-methylated-glioblastoma-in-the-randomized-glarius-trail-2/ 2022-11-04T13:59:00+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/n%c2%b2m%c2%b2-noa-20-phase-i-ii-trial-of-molecularly-matched-targeted-therapies-plus-radiotherapy-in-patients-with-newly-diagnosed-non-mgmt-hypermethylated-glioblastoma/ 2022-11-04T13:07:06+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/n%c2%b2m%c2%b2-noa-20-phase-i-ii-trial-of-molecularly-matched-targeted-therapies-plus-radiotherapy-in-patients-with-newly-diagnosed-non-mgmt-hypermethylated-glioblastoma-2/ 2022-11-04T13:07:00+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/health-related-quality-of-life-and-neurocognitive-functioning-with-lomustine-temozolomide-versus-temozolomide-in-patients-with-newly-diagnosed-mgmt-methylated-glioblastoma-ceteg-noa-09-a-randomise/ 2022-11-04T13:06:39+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/health-related-quality-of-life-and-neurocognitive-functioning-with-lomustine-temozolomide-versus-temozolomide-in-patients-with-newly-diagnosed-mgmt-methylated-glioblastoma-ceteg-noa-09-a-randomise-2/ 2022-11-04T13:06:32+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/lomustine-temozolomide-combination-therapy-versus-standard-temozolomide-therapy-in-patients-with-newly-diagnosed-glioblastoma-with-methylated-mgmt-promotor-ceteg-noa-09-a-randomised-open-label-ph/ 2022-11-04T13:03:50+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/lomustine-temozolomide-combination-therapy-versus-standard-temozolomide-therapy-in-patients-with-newly-diagnosed-glioblastoma-with-methylated-mgmt-promotor-ceteg-noa-09-a-randomised-open-label-ph-2/ 2022-11-04T13:03:47+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/baseline-t1-hyperintense-and-diffusion-restricted-lesions-are-not-linked-to-prolonged-survival-in-bevacizumab-treated-glioblastoma-patients-of-the-glarius-trail/ 2022-11-04T13:03:44+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/neurocognitive-functioning-and-health-related-quality-of-life-in-adult-medulloblastoma-patients-long-term-outcomes-of-the-noa-07-study-2/ 2022-11-04T13:02:13+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/neurocognitive-functioning-and-health-related-quality-of-life-in-adult-medulloblastoma-patients-long-term-outcomes-of-the-noa-07-study/ 2022-11-04T13:02:08+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/bevacizumab-plus-irinotecan-versus-temozolomide-in-newly-diagnosed-06-methylguanine-dna-methyltransferase-nonmethylated-glioblastoma-the-randomized-glarius-trial-2/ 2022-11-03T14:49:19+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/blog/publikationen/interim-results-from-the-catnon-trial-eortc-study-26053-22054-of-treatment-with-concurrent-and-adjuvant-temozolomide-for-1p-19q-non-co-deleted-anaplastic-glioma-a-phase-3-randomised-open-label-in/ 2022-11-03T14:00:22+00:00 https://neuroonkologische-arbeitsgemeinschaft.de/en/blog/publikationen/interim-results-from-the-catnon-trial-eortc-study-26053-22054-of-treatment-with-concurrent-and-adjuvant-temozolomide-for-1p-19q-non-co-deleted-anaplastic-glioma-a-phase-3-randomised-open-label-in-2/ 2022-11-03T13:50:22+00:00